THERALASE TECHS INC - TLTFF STOCK NEWS

Theralase Technologies (TSXV: TLT; OTCQB: TLTFF) announced that interim data from its Phase II Non-Muscle Invasive Bladder Cancer (NMIBC) clinical study has been accepted for presentation at the ASCO GU Cancer Symposium in San Francisco, occurring from February 16 to 18, 2023. The poster, titled "A Phase II Clinical Study of Intravesical Photo Dynamic Therapy in Patients with BCG-Unresponsive NMIBC," will be presented on February 17, 2023. This study aims to evaluate the efficacy of TLD-1433, a patented photo dynamic compound.

Theralase Technologies Inc. (TLTFF) announced its unaudited financial results for Q3 2022, showing a 43% year-over-year revenue increase to approximately $813,000.

Notable financial metrics include a gross margin of 52% and a net loss of $4.35 million, influenced heavily by increased research and development expenses. Key operational highlights include ongoing clinical studies and advancements in anti-cancer therapies, including the development of a COVID-19 vaccine. Despite delays due to the pandemic, patient enrollment rates in clinical studies are improving.

Theralase Technologies Inc. (TLTFF) announced a proposal to extend the expiry date of 3,157,059 share purchase warrants from October 3, 2022, to October 3, 2023. These warrants, exercisable at $0.50 per share, were initially issued as part of a private placement in 2018. The extension is pending final acceptance by the TSX Venture Exchange. Theralase specializes in developing light-activated compounds for cancer treatment, emphasizing both efficacy and safety in its formulations.

Theralase Technologies Inc. (TSXV: TLT, OTCQB: TLTFF) has successfully closed a non-brokered private placement, issuing 10,000,000 units at $0.25 each, raising approximately $2,500,000. Each unit comprises one common share and one warrant, exercisable at $0.35 for 24 months. Proceeds will fund GLP Toxicology studies for Rutherrin, advance Phase II NMIBC clinical studies, and general corporate needs. The offering included insider subscriptions of 2,400,000 units worth $600,000, exempt from formal valuation requirements. All securities are subject to a four-month hold period.

Theralase Technologies Inc. (TSXV: TLT, OTCQB: TLTFF) has released its unaudited 2Q2022 financial results, showing a 28% increase in total revenue year-over-year, totaling CAD 552,442. The gross margin rose to 51%, up from 46% in 2021. Operating expenses surged by 43% to CAD 3,227,954, primarily due to higher research and development costs, which rose 68%. The net loss for the period was CAD 2,947,168, exacerbated by increased spending in its ACT division. Operational highlights include updates on patient enrollment and ongoing clinical studies.

Theralase Technologies Inc. (TLTFF) announced the granting of a Brazilian patent for its Metal-Based Thiopene Photodynamic Compounds. This patent enhances Theralase's international intellectual property portfolio, focusing on its Anti-Cancer Technology (ACT) platform. The patent supports the ongoing Phase II clinical study of TLD-1433 for treating Non-Muscle Invasive Bladder Cancer (NMIBC). Currently, 41 patients have been treated across 12 sites. The company aims to commercialize ACT technology and expand its therapeutic applications to various cancers, enhancing shareholder value.

Theralase Technologies, a clinical-stage pharmaceutical company, announced the peer-reviewed publication of its Phase Ib clinical study on non-muscle invasive bladder cancer (NMIBC) in the European Urology Open Science Journal. The study evaluated TLD-1433, a light-activated compound, which showed promise for patients unresponsive to Bacillus Calmette-Guérin (BCG) treatment. The results demonstrated safety and potential efficacy, leading to the initiation of a multi-site Phase II study at 12 sites. The company aims to enroll 100-125 patients and assesses primary efficacy and safety outcomes.

Theralase Technologies Inc. (TLTFF) reported its 1Q2022 financial results, showing a 70% increase in total revenue to $211,662 compared to $124,783 in 2021. Gross margin improved to 43%, while net loss rose to $1,701,489, an 85% increase year-over-year largely due to elevated R&D expenses. The company's Fast Track Designation from the FDA for its Study II allows for frequent communication on trials. Despite setbacks from the COVID-19 pandemic, patient enrollment in clinical studies is progressing, with new anti-cancer indications being explored and COVID-19 vaccine development ongoing.